Emergent BioSolutions has signed a marketing agreement with Biological E for the marketing of BioThrax in India. BioThrax is the only vaccine for the prevention of anthrax infection licensed by the FDA, the company said.
Fuad El-Hibri, chairman and CEO of Emergent BioSolutions, said: “The Government of India has been explicit in expressing its commitment to protect its population from the continuing threat of bioterrorism. We are certainly pleased that BioThrax will be a valuable countermeasure available to the Government of India to achieve that goal.”